Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management.

針對第二型糖尿病與肥胖治療的新型GLP-1、GIP、Glucagon及GDF15雙重與三重作用劑